NCT05673109

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Terminated Phase 1 Last updated 25 January 2024

What this trial tests

Phase 1 trial testing AC176 in Metastatic Castration Resistant Prostate Cancer in 8 participants. Terminated before completion.

Timeline

22 February 2023

Primary endpoint
8 October 2023

8 October 2023

Quick facts

Lead sponsor	Accutar Biotechnology Inc
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	22 February 2023
Primary completion	8 October 2023
Estimated completion	8 October 2023
Sites	5 locations across China

Drugs / interventions tested

• AC176 — full drug profile →

Conditions studied

• Metastatic Castration Resistant Prostate Cancer — all drugs for Metastatic Castration Resistant Prostate Cancer →

Sponsor

Accutar Biotechnology Inc — full company profile →

Who can join

18 and older, male only, with Metastatic Castration Resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.

The main goals of this study are to:

Evaluate the safety and tolerability of AC176, evaluate pharmacokinetics and preliminary antitumor activity of AC176

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeted protein degradation: advances in drug discovery and clinical practice.
   Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
2. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders.
   Ma Z, Zhou J. · · 2025 · cited 28× · PMID 40702893 · DOI 10.1021/acs.jmedchem.5c01818
3. RIPTACs: A groundbreaking approach to drug discovery.
   Ma Z, Bolinger AA, Zhou J. · · 2023 · cited 20× · PMID 37734702 · DOI 10.1016/j.drudis.2023.103774
4. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
   Bouvier C, Lawrence R, Cavallo F, Xolalpa W, et al · · 2024 · cited 14× · PMID 38607017 · DOI 10.3390/cells13070578
5. Proteolysis-Targeting Chimera (PROTAC): Current Applications and Future Directions.
   Fan G, Chen S, Zhang Q, Yu N, et al · · 2025 · cited 6× · PMID 41049269 · DOI 10.1002/mco2.70401
6. Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment.
   Anaya YA, Barragan M, Bracho RP, Shaham SH, et al · · 2025 · cited 3× · PMID 41108678 · DOI 10.1002/cncr.70132
7. Advances in the treatment of metastatic prostate cancer in China.
   Wang B, Liu Z, Yang L, Zhang X. · · 2025 · cited 1× · PMID 40387589 · DOI 10.20892/j.issn.2095-3941.2025.0065
8. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.
   Knoll N, Neamati N, Üren A. · · 2026 · PMID 41988372 · DOI 10.1021/acsptsci.5c00730